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Abstract
Rationale and Objectives: Adiposity and physical fitness levels are major drivers of
cardiometabolic risk, but these relationships have not been well-characterized in chronic kidney
disease (CKD). We examined the associations of visceral adipose tissue (VAT), subcutaneous
adipose tissue (SAT), intrahepatic fat and physical function with inflammation, insulin resistance,
and adipokines in patients with CKD.
Study Design: Prospective cohort study
Setting and Participants: Participants with Stage 3–5 CKD not receiving chronic dialysis,
followed at one of 8 clinical sites in the Chronic Renal Insufficiency Cohort study, and who
underwent MRI of the abdomen at an annual CRIC Study visit (n=419)

Author Manuscript

Predictors: VAT volume, SAT volume, intrahepatic fat, body mass index (BMI), waist
circumference (WC), and time taken to complete the 400 m walk test (physical function)
Outcomes: Markers of inflammation (IL1-beta, IL-6, TNF-R1, and TNF-R2), insulin resistance
(HOMA-IR), and adipokines (adiponectin- total and high molecular weight [HMW], resistin, and
leptin).
Analytical Approach: Multivariable linear regression of VAT and SAT volume, intrahepatic fat
and physical function, with individual markers (log-transformed values) adjusting for relevant
covariates

Author Manuscript

Results: Mean age of the study population was 64.3 years; 41% were females, and the mean
eGFR was 53.2 (+/− 14.6) ml/min/1.73 m2. Over 85% were overweight or obese, and 40% had
diabetes. Higher VAT volume, SAT volume, and liver proton density fat fraction, were associated
with lower levels of total and HMW adiponectin, higher levels of leptin and insulin resistance,
lower HDL cholesterol and higher serum triglycerides. A slower 400m walk time was associated
only with higher levels of leptin, total adiponectin, plasma IL-6 and TNFR-1 and did not modify
the associations between fat measures and cardiometabolic risk factors.
Limitations: Lack of longitudinal data and dietary details
Conclusions: Various measures of adiposity are associated with cardiometabolic risk factors.
Physical function was also associated with the cardiometabolic risk factors studied and does not
Am J Kidney Dis. Author manuscript; available in PMC 2022 January 01.
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modify the associations between fat measures and cardiometabolic risk factors. Longitudinal
studies of the relationship between body fat and aerobic fitness with cardiovascular and kidney
disease progression are warranted.
Keywords
Obesity; fat; physical function; kidney disease; cardiometabolic risk factor

Introduction

Author Manuscript

In the general population, regional fat distribution rather than overall obesity is recognized
as a key factor in the link between obesity and cardiovascular disease1. Central abdominal
obesity is a better predictor of cardiovascular disease than overall obesity as assessed by
body mass index (BMI). Importantly, various abdominal fat compartments and distributions
have different associations with cardiometabolic risk factors in those without kidney
disease2–7. However, such relationship in the setting of CKD have not been explored
previously. Experimental studies have explored multiple mechanisms underlying the
development and progression of kidney disease in the setting of obesity8. In both overweight
and obesity, increases in renal plasma flow and glomerular hyperfiltration leading to an
increased interglomerular pressure are noted. . Furthermore, through the renin-angiotensinaldosterone system, adipose tissue also contributes to glomerular arteriolar modulation with
changes in intraglomerular pressure and filtration fraction9.

Author Manuscript
Author Manuscript

Pro-inflammatory adipokines including adiponectin have been linked to increased urinary
protein excretion and cardiovascular disease in patients with obesity10. Leptin, a 16-kDa
peptide plays a key role in food intake and energy expenditure and may contribute to the
progression of kidney disease secondary to the proliferation of endothelial cells and
mesangial cell hypertrophy11. Data indicate that there may be a differential relationship
between visceral and subcutaneous fat and inflammatory adipokines in the general
population but whether these associations are similar among those with CKD is unknown. In
addition, we know relatively little about the role of physical fitness and cardiovascular risk
in CKD. In diabetic and non-diabetic populations (with preserved kidney function), higher
physical fitness levels (independently) among those with higher BMI are associated with a
lower prevalence of cardiovascular risk factors and mortality compared to those with normal
BMI and lower fitness level12–14. Indeed, fitness and adiposity may have independent or
synergistic relationships with mechanistic pathways for adverse outcomes, individual
cardiometabolic risk factors, and clinical outcomes in CKD. Therefore, we examined the
associations of visceral adipose tissue (VAT)/subcutaneous adipose tissue (SAT) (assessed
using MRI), other obesity measures, and physical function (measured using 400 m walk test,
a surrogate measure of physical fitness) with inflammation, insulin resistance, adipokines
and lipid parameters among individuals with CKD participating in the Chronic Renal
Insufficiency Cohort (CRIC) Study.

Am J Kidney Dis. Author manuscript; available in PMC 2022 January 01.
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Methods
CRIC study
In the first phase of the CRIC study (2003–2008)-an ongoing multicenter observational
cohort study, 3939 adults aged 21–74 years with an eGFR of 20–70 ml/min/1.73 m2 were
recruited from 13 discrete clinical research sites. Later in 2013 (phase 3), an additional 1560
individuals with mild-moderate CKD were recruited and are also currently being followed.
Details of the CRIC study have been published previously15.
CRIC VAP study

Author Manuscript

We enrolled 449 patients for the CRIC Visceral Adiposity and Physical function (CRIC
VAP) study from 8 clinical sites, as an ancillary to the parent CRIC study. CRIC participants
aged 21–79 years with an eGFR 25–74 ml/min/1.73 m2 who were enrolled in Phases 1 and 3
of CRIC were eligible for inclusion. Participants who were on dialysis or had received a
kidney transplant, had severe osteoarthritis or peripheral vascular disease precluding
participation in a 400 m walk test and/or could not undergo an MRI exam (with metallic
implants, pacemaker, claustrophobia, etc.) were excluded. All eligible participants who
participated in a 400 m walk test to assess physical functional status and had an MRI to
quantify visceral, subcutaneous and intrahepatic fat content. The study protocol was
approved by the Institutional Review Board at each of the participating sites. All study
participants were consented at their primary sites prior to enrollment.
Covariates

Author Manuscript

400 m walk test

Author Manuscript

Age, sex, race, smoking, alcohol intake details, comorbid conditions and medication use
were obtained at routine study visits. BMI was calculated as weight in kilograms divided by
height in meters squared, and waist circumference was measured at the uppermost lateral
border of the iliac crest with a Gulick II tape measure.

MRI imaging

A 400 m walk test was administered during routine CRIC study visits to assess physical
function and as an indicator of aerobic capacity16,17. The test was administered in an open
corridor of the clinical unit with two cones spaced 20 m apart. Participants walked 10 laps
around the cones for a total of 400 m and were given standard encouragement at each lap.
Heart rate was recorded for each lap, and blood pressure was measured at the end of the test.
Completion time for the 400 m walk was recorded in seconds. If the participant felt a need to
stop and rest, they were allowed to stand in one place and rest. Participants could not lean
against a wall, table or elsewhere. Stopping criteria for the test included: (1) if the
participant reported chest pain, tightness or pressure in the chest, shortness of breath, feeling
faint, lightheaded or dizzy, or severe leg pain, or (2) test duration over 15 minutes.

Visceral and subcutaneous adipose tissue volume were assessed by magnetic resonance
imaging using a standardized protocol. Images of the abdominal cavity were obtained using
a Siemens, GE or Philips MR system based on availability at the participating sites. The

Am J Kidney Dis. Author manuscript; available in PMC 2022 January 01.
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quantitative 6-point Dixon proton density fat fraction (PDFF) measurement consisted of
multiple 3D axial acquisitions spanning the dome of the liver to the symphysis pubis using
5mm slices. Typically, three breath-hold 3D slabs (obtained at end expiration) were needed
to cover this distance, with a minimum of 2 slabs and a maximum of 4 slabs used. Images
were reconstructed, combined, and post-processed automatically using the FDA approved
commercial PDFF software for each MR system. VAT and SAT volume were quantified
using an automated algorithm described in more detail by Addeman et al18, with a trained
observer correcting errors when applicable. The automated segmentation algorithm applies a
three-stage process to identity and segment VAT and SAT using fat, water, and PDFF images
collected with 6-point Dixon MR technique. Using the combined fat and water image series,
the dataset is pre-processed to identify the torso volume from background noise using
adaptive k-means clustering. Adipose tissue was then identified by applying the torso
volume to the PDFF image and filtering for PDFF values above 70% followed by a region
growing algorithm to identify connected partial-volume adipose tissue above 50% PDFF.
Finally, SAT and VAT were separated by fitting a 3D surface to the muscles that are
proximal to the subcutaneous adipose. Intrahepatic fat content (% PDFF) was obtained by a
trained observer placing a circular region-of-interest on a single slice in the PDFF image
series and documenting the average PDFF value within the region of interest. A healthy
volunteer scan was obtained prior to the study initiation to implement corrective measures to
ensure consistency/accuracy of the protocol at each site.
Metabolic Assessments

Author Manuscript

Blood samples were obtained to determine fasting glucose, insulin, leptin, resistin, total/high
molecular weight adiponectin, IL-6, IL-1 beta, TNFR1, and TNFR2 concentrations. Plasma
insulin was determined via radioimmunoassay (EMD Millipore, Billerica, MA, USA) and
insulin resistance was determined using the homeostasis model assessment of insulin
resistance (HOMA-IR)19. IL-6, IL-1 beta, TNFR1, TNFR2, resistin, leptin, total and high
molecular weight adiponectin were analyzed via ELISA (R&D systems, Minneapolis, MN,
USA). All samples were stored at −80°C, and assays were performed at the time of initial
thawing. All assays were performed in duplicate, and mean values were used in the analysis.

Statistical analysis

Author Manuscript

Clinical and demographic characteristics of the study cohort were tabulated (Table 1).
Continuous (biomarkers) variables were checked for skewness and log transformed if they
were not normally distributed. We examined SAT and VAT volume within various categories
of BMI (18.5–24.99, 25–29.9, and >30) and WC (high or normal: < 88cm in women and
<102 cm in men) using Kruskal-Wallis tests. The associations between SAT and VAT and
categories of both BMI and WC were examined separately for men and women using the
Kruskal-Wallis test. Boxplots were created for SAT and VAT based on stages of kidney
disease (stage 3a, 3b and 4) and based on time to complete the 400 m test by quartiles of
SAT and VAT. Spearman correlations of VAT, SAT, liver PDFF, BMI, WC and 400 m walk
time were performed with each of the cardiometabolic risk factors.

Am J Kidney Dis. Author manuscript; available in PMC 2022 January 01.
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A separate multivariable regression model was constructed for each SD increase in VAT,
SAT, intrahepatic fat (liver PDFF), and 400 m walk time as the independent variable and
each of the cardiometabolic risk factors as the dependent variable. Cardiometabolic markers
were log transformed except for LDL-cholesterol. We did not fit regression models for IL-1
beta as more than half of participants had undetectable levels. We adjusted each model for
age, sex, race, diabetes, hypertension, hypercholesterolemia (except for outcomes- HDL,
LDL and triglycerides), cardiovascular disease, eGFR and proteinuria. Regression models
for 400 m walk test were also adjusted for BMI. Due to co-linearity between BMI and
VAT/SAT/intrahepatic fat, we did not adjust for BMI in the multivariable models of VAT/
SAT. We also examined VAT/SAT as categorical variables (as quartiles) and studied their
relationship with the same cardiometabolic factors. We evaluated 2-way interactions
between predictors that were statistically significant in the primary models and sex, and
diabetes. We also evaluated the previously mentioned SAT and VAT models including an
interaction with physical activity. Covariate data were missing for: BMI (n=1), eGFR (n=2),
and urine protein:creatinine ratio (n=26). We used multiple imputation (SAS proc MI) with
the Markov Chain Monte Carlo method and a single chain to impute 5 datasets with
complete covariate data. All regression models were performed on each of the 5 imputed
datasets and parameter estimates were combined with SAS MI analyze.

Author Manuscript

All statistical analyses were conducted with Linux SAS version 9.4 (SAS Institute, Cary,
NC) and graphs were created using R 3.5.1 (The R Foundation for Statistical Computing,
Vienna, Austria). A 2-sided p-value of 0.05 was used to determine statistical significance.

Results
Baseline characteristics

Author Manuscript
Author Manuscript

Of the 449 participants consented, 432 completed the 400 m walk test; 419 completed the
MRI scan, and 409 subjects completed both the walk test and MRI assessment. The 419
participants who completed the MRI exam are included in this study (Figure S1). Mean age
of the study population was 64.3 ± 8.5 years; 41% were female, 47.5% were non-Hispanic
blacks. Over 85% of participants were overweight or had obesity (BMI >25 kg/m2), and
40% had diabetes. Mean eGFR was 53.2 ± 14.6 ml/min/1.73 m2 with a mean urine protein
excretion of 0.56 g per day. Other baseline characteristics are presented in Table 1. Median
(25th–75th percentile) VAT volume was 5993 mL (3987, 8768) mL, SAT volume was 9405
(6057, 13715) mL and intrahepatic fat was 4.3 (2.7, 7.4) %. All participants completed the
400 m walk test and the median (25th-75th percentile) time taken to complete the test was
384 (334,441) seconds. Details of the baseline lipid parameters, adipokines and
inflammatory marker are outlined in Table 1. Baseline VAT and SAT levels based on BMI
and WC categories and stratified by gender are presented in Table S1.
Correlations between VAT, SAT, Physical function and other adiposity measures
Time taken to complete the 400 m walk test among those with different levels of SAT and
VAT are shown in Table S2. Spearman correlations of VAT, SAT, intrahepatic fat, BMI, WC
and 400 m walk test time with metabolic risk factors are displayed in Table 2. VAT, SAT and
intrahepatic fat were inversely correlated with total and HMW adiponectin. VAT and

Am J Kidney Dis. Author manuscript; available in PMC 2022 January 01.
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intrahepatic fat were also inversely correlated with HDL cholesterol. VAT, SAT and liver fat
were positively correlated with leptin, HOMA-IR, and triglycerides. Similar correlations
were also noted for BMI and WC with the cardiometabolic factors. On the other hand,
higher levels of physical function was correlated only with leptin, resistin and inflammatory
markers.
Associations of adiposity measures and physical function with cardiometabolic factors

Author Manuscript

Continuous variables—The results of the multivariable-adjusted linear regression
analyses for the association of VAT and SAT volume, intrahepatic fat and physical function
with continuous metabolic risk factors are summarized in Table 3. Each SD higher VAT and
SAT volume and intrahepatic fat were associated with lower levels of total and HMW
adiponectin and HDL cholesterol, and higher levels of leptin, insulin resistance and serum
triglyceride levels. Each SD higher 400m walk time was associated only with higher levels
of total adiponectin, leptin, plasma IL-6 and TNFR-1.
Categorical variable—The results of the multivariable-adjusted linear regression analyses
for the association of VAT, SAT or liver PDFF as categorical variables (quartiles) with
metabolic risk factors are summarized in Table S3. These results were qualitatively similar
to the results of the continuous analyses.

Author Manuscript

Effect modifiers—The relationship between VAT and log transformed total adiponectin
varied by sex (interaction term p= 0.04) suggesting that while the relationship between VAT
and adiponectin was significant for both sexes, it was stronger for women than for men
(women estimate per 1 SD higher −0.44, SE 0.09, men estimate −0.25, SE 0.05). The
association of hepatic PDFF and log transformed HOMA-IR also varied by sex. There also
was a significant interaction between liver PDFF and sex on log transformed HOMA-IR,
(p=0.01) while higher liver PDFF was associated with higher HOMA-IR in both sexes, the
association was stronger for women (women estimate per 1 SD higher 0.39, SE 0.07, men
estimate 0.13, SE 0.06). No other significant interactions were noted with sex. No significant
interactions were noted with diabetes. There was a significant interaction between VAT and
400 m walk time on log leptin (p=0.008). When we explored the interaction categorizing
VAT above and below the median, the interaction was no longer significant, but a longer
400m walk time was associated with an additional increase in log leptin for those with
visceral fat above the median VAT.

Discussion
Author Manuscript

In a cohort of men and women with varying degrees of CKD, a higher VAT volume, SAT
volume and visceral fat deposits reflected by intrahepatic fat were associated with higher
inflammatory burden, insulin resistance, altered adipokines profile and lower HDL
cholesterol and higher triglyceride levels. These associations were similar to the relationship
of other traditional measures of adiposity such as BMI and WC, with inflammation, insulin
resistance and adipokines. Physical fitness was assessed by time taken to complete the 400
m walk test and was associated only with higher levels of leptin and higher inflammatory
burden, and not with other adipokines and insulin resistance. Higher levels of physical

Am J Kidney Dis. Author manuscript; available in PMC 2022 January 01.
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fitness did not modify the associations between adiposity measures and cardiometabolic risk
factors in CKD.
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Adverse consequences of visceral fat have been attributed to several different mechanistic
pathways as follows3. The increase in visceral fat is likely a response to an inability to
increase SAT in the setting of positive caloric balance. Previous epidemiological
investigations in the general population have shown a relationship between various fat
depots and cardiometabolic risk factors. Data from the Framingham Heart Study
demonstrated that both higher VAT volume and SAT volume were negatively correlated with
total adiponectin and resistin, but were positively associated with systemic inflammation
(IL-6, C-Reactive protein)4,20. In the Dallas Heart study, higher VAT was associated with
lower adiponectin, enhanced insulin resistance, and abnormal HDL cholesterol levels. In
contrast, SAT was associated with increased leptin and inflammatory markers, but not with
insulin resistance, dyslipidemia and other cardiovascular risk factors21. Similar findings
were also noted by the Jackson Heart Study investigators6. In contrast to the general
population, the role of SAT/VAT with adipokines, inflammation and insulin resistance have
not been examined in those with CKD. Our findings extend our understanding of these
critical associations by characterizing them among a large cohort of individuals with CKD.
Further, within this population, these relationships seem to be consistent across the sexes
unlike what has been noted in the general population22,23. It is critical to note that our cohort
is older (mean age 64 years vs 46 years in FHS and 44 in the DHS) and also had higher
comorbidity burden unlike other study cohorts. Whether the differential associations of VAT
and SAT noted in younger populations change with aging and development of comorbidity
burden (as noted in our study) is unclear.
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Similar to our findings, data from other community-based cohorts also observed higher
correlation for both VAT and SAT with BMI/WC, and the association between VAT/SAT
with the cardiometabolic factors were independent of overall adiposity21,24. We didn’t adjust
for BMI/WC in the multivariable models due to high collinearity in the models. CKD per se
is associated with higher CV disease burden, which is mediated in part, by greater
inflammation, oxidative stress and insulin resistance. In the Framingham Heart Study, both
VAT/SAT were associated with incident cardiovascular risk factors (hypertension, diabetes,
HDL cholesterol) during a follow-up of 6 years25. We were unable to study this prospective
relationship in our study population without pre-existing cardiovascular disease. Whether
such a phenomenon exists in CKD is unknown and merits further investigation.
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Finding that all metrics of adiposity assessed in our study had similar associations with
cardiometabolic risk factors is notable. While MRI metrics are not readily available in
clinical settings, BMI and WC can be easily measured. It is important to note that in both
dialysis and non-dialysis dependent CKD, higher levels of BMI, but not WC have been
associated with a lower risk of mortality26,27. Our observation that higher levels of BMI,
WC, VAT and SAT were associated with a higher burden of cardiometabolic risk argues for
longitudinal studies to assess if these observations will translate to higher CV events and
mortality. Body fat distribution varies even within the same BMI range with some having a
higher VAT while some with lower level28. Whether higher levels of VAT within different
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categories of SAT are associated with altered metabolic profile is of interest and warrants
further study.
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Data from the Framingham Health Study noted that intrahepatic fat was associated with
cardiometabolic risk factors including an abnormal lipid profile and elevated BP; however
data linking intrahepatic fat with adipokines and inflammatory markers are limited29. Our
study provides novel data about the relationship between intrahepatic fat and metabolic risk
factors in CKD. Higher liver PDFF was associated with several cardiometabolic risk factors
including serum triglycerides in this cohort. Even though the exact mechanism for these
observed associations are unclear, this may be because VAT and liver PDFF often influence
both glucose regulation and lipid metabolism30. Higher VAT increases lipolytic activity
leading to an increased delivery of hepatic fatty acids to the liver via the portal vein. The
increased hepatic fatty acid load in turn increases serum triglyceride levels and contributes to
hepatic insulin resistance.
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Conflicting data exist regarding the relationship between various fat deposits and the risk of
decline in kidney function. Data from the Framingham Offspring study shows that VAT and
SAT are associated with CKD when eGFR was calculated using the cystatin C based
equation, but not with MDRD31. In the Health ABC cohort, SAT, VAT, IMAT ((Intermediate
Muscular Skeletal Assessment and Treatment), BMI, and WC (per SD increase) were
significantly associated with a decline in kidney function and the authors concluded that
anthropometric measures of body fat appear to provide an estimate of the risk of kidney
function decline that is consistent with estimates based on CT measures of VAT, SAT32. We
did not observe any correlation between baseline kidney function and VAT, SAT and liver
PDFF in those with established CKD. Thus, whether these have any differential associations
with kidney function decline will require future study.
Contrary to our hypothesis, performance on the physical function test did not alter the
associations between fat measures and cardiometabolic factors. However, a higher level of
physical fitness was associated with higher leptin and adiponectin levels in our cohort. Both
in community-dwelling older men and women, higher leptin is associated with increased
risk of impaired physical function33. Older adults with sarcopenic obesity (especially those
with CKD) are also at higher risk of impaired physical function due to a loss of skeletal
mass and strength from chronic inflammation and oxidative stress. The association between
adiponectin and physical function has been attributed to a decline of skeletal muscle
function34,35. While we did not formally assess skeletal muscle function, our observations
are consistent with this observation.
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Strengths of our study include a relatively large sample of patients with clinically diagnosed
chronic kidney disease, the use of MRI to precisely quantify VAT, SAT and intrahepatic fat,
and a validated protocol to assess aerobic fitness in patients with kidney disease. Further,
fidelity of the MRI measure was assured by using the same standardized protocol at each
site. We did not restrict the study to those with obesity and enrolled patients with different
levels of BMI thereby increasing generalizability. Despite its strengths, we acknowledge
limitations. Given the cross-sectional associations, causal relationship among adiposity
measures, and cardiometabolic risk factors cannot be established. We enrolled patients who
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are being followed in health systems (actively seeking care) and hence whether these data
are applicable to those with CKD in the community is unclear.
In summary, different adiposity measures such as BMI, WC, VAT and SAT are associated
with various cardiometabolic risk factors highlighting the harmful effects of obesity in CKD.
Physical function, as assessed by a 400m walk test was associated with some, but not all
cardiometabolic risk factors studied. Notably, level of physical function did not modify the
associations between fat measures and the cardiometabolic risk factors. A deeper
understanding of the reasons for these differential associations may lead to new approaches
to management of patients with CKD. Longitudinal studies addressing the relationship
between measures of body fat and aerobic fitness with cardiovascular and kidney disease
progression are warranted.
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PLAIN-LANGUAGE SUMMARY

Author Manuscript

Obesity as assessed by body mass index is associated with an increased risk of heart
disease and progression of kidney disease in those with chronic kidney disease (CKD). In
this cohort of patients with CKD, we studied whether different obesity measures such as
intra-abdominal fat, liver fat and sub cutaneous fat (obtained using an MRI scan) were
associated with known cardiometabolic risk factors. We further assessed whether
physical function (measured using a 400 m walk test) was independently associated with
the same cardiometabolic risk factors. Our analysis suggests that all measures of higher
fat content were associated with an increased level of cardiometabolic risk factors. While
slower walk time were associated with an increased level of cardiometabolic risk factors,
it did not modify the associations between fat measures and these risk factors. In
summary, these data highlight that various abdominal fat measures and lower physical
fitness levels are associated with a higher cardiovascular risk in those with CKD.
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Figure 1—.

Boxplot of SAT and VAT by stage of CKD

Author Manuscript
Am J Kidney Dis. Author manuscript; available in PMC 2022 January 01.

Navaneethan et al.

Page 15

Author Manuscript
Author Manuscript
Author Manuscript

Figure 2—.

Boxplot of 400 m walk test time by quartiles of SAT and VAT
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Table 1.

Author Manuscript

Baseline characteristics of study population
Factor

Total (N=419)

Age (years)

64.3±8.5

Female, N (%)

170(40.6)

Race, N (%)

182(43.4)

Non-Hispanic White
Non-Hispanic Black

199(47.5)

Hispanic

28(6.7)

Other

10(2.4)

Education category, N (%)

Author Manuscript

Less than high school

48(11.5)

High school graduate

72(17.2)

Some college

109(26.0)

College graduate or higher

190(45.3)

BMI

(kg/m2),

N (%)

18.5–24.9

61(14.6)

25–29.9

150(35.9)

30–39.9

179(42.8)

>40

28(6.7)

Author Manuscript

Weight (kg)

89.2±18.7

Waist Circumference (cm)

104.6±14.6

Systolic BP (mmHg)*

126.7±18.6

Diastolic BP (mmHg)*

69.7±12.0

eGFR (ml/min/1.73 m2)*

53.2±14.6

CKD stage (ml/min/1.73 m2, %), N (%)
≥90

4(0.96)

60 – <90

125(30.0)

45 – <60

174(41.7)

30 – <45

93(22.3)

15 – <30

19(4.6)

<15

2(0.48)

Urine Protein/Creatinine Ratio (g/g)

0.17[0.07,0.59]

Hemoglobin A1C (%)

6.5±1.4

Author Manuscript

Chronic medical conditions, N (%)
Atrial fibrillation/other arrhythmia

64(15.3)

Cardiovascular disease

98(23.4)

Congestive heart failure

20(4.8)

Peripheral vascular disease

16(3.8)
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Factor

Total (N=419)

Author Manuscript

CVA

38(9.1)

Chronic Obstructive Pulmonary Disease

48(11.6)

Diabetes

166(39.6)

Family History of CAD

19(4.5)

Hyperlipidemia

345(82.3)

Hypertension

393(93.8)

Author Manuscript

Smoking (both previous and current)

190(45.3)

Alcohol Use

266(64.1)

Use of ACE Inhibitors or ARBs (%)

278(66.3)

Lipid-lowering drug use (%)

264(63.0)

Glucose (mg/dl)

118.0±45.7

Total cholesterol (mg/dl)

178.0[147.5,208.5]

LDL cholesterol (mg/dl)

101.0[77.0,130.0]

HDL cholesterol (mg/dl)

44.0[36.0,55.0]

Triglycerides (mg/dl)

125.0[89.0,179.0]

Adipokines, inflammatory markers

Author Manuscript

Total adiponectin ng/ml

6840[4247,12429]

HMW adiponectin ng/ml

3795[2147,6455]

Leptin pg/ml

29363[13252,59090]

Resistin ng/ml

13.0[9.4,18.4]

TNFR1 pg/ml

2429[1888,3308]

TNFR2 pg/ml

4086[3147,5607]

IL1 beta pg/ml

0.00[0.00,0.21]

IL-6 pg/ml

2.4[1.6,3.9]

MRI data
Visceral adipose tissue volume, L

5.99[3.98,8.76]

Subcutaneous adipose tissue volume, L

9.40[6.05,13.71]

Intrahepatic fat (PDFF %)

4.3(2.7, 7.4)

400 m walk time (seconds)

384 [334, 441]

*

Data not available for all subjects. Missing values: Body Mass Index (kg/m) = 1, Diastolic BP (mmHg) = 5, eGFR - CKD EPI Equation (ml/min/
1.73m) = 2, Glucose (mg/dL) = 2, Height (cm) = 1, Urine Protein/Creatinine Ratio from spot sample = 26, Serum Albumin (g/dL) = 2, Systolic BP
(mmHg) = 4, 24H Urine Protein (g/24H) = 303, History of Chronic Obstructive Pulmonary Disease (emphysema) = 6, Statistics presented as Mean
± SD, Median [P25, P75], or column %.
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Am J Kidney Dis. Author manuscript; available in PMC 2022 January 01.

Author Manuscript

Author Manuscript

Author Manuscript
373
402
403
403
402
376
375
375

IL1B

IL6

TNFAR1

TNFAR2

HDL cholesterol

LDL cholesterol

Triglycerides

403

Leptin

HOMA-IR

402

HMW Adiponectin

402

402

Total Adiponectin

Resistin

N

Factor

0.34 (0.24, 0.42)

−0.09 (−0.19, 0.01)

−0.35 (−0.44, −0.26)

−0.03 (−0.12, 0.07)

0.02 (−0.08, 0.11)

0.07 (−0.03, 0.17)

0.17 (0.07, 0.26)

0.27 (0.17, 0.36)

0.04 (−0.06, 0.14)

0.15 (0.05, 0.24)

−0.40 (−0.48, −0.31)

−0.39 (−0.47, −0.30)

VAT rho (95% CI)

<0.001

0.07

<0.001

0.6

0.8

0.2

<0.001

<0.001

0.4

0.003

<0.001

<0.001

p-value

375

375

376

402

403

403

402

373

402

403

402

402

N

0.14 (0.04, 0.24)

0.13 (0.03, 0.23)

−0.01 (−0.11, 0.09)

−0.08 (−0.18, 0.01)

−0.11 (−0.20, −0.01)

0.15 (0.06, 0.25)

0.17 (0.07, 0.26)

0.24 (0.14, 0.33)

−0.02 (−0.12, 0.08)

0.66 (0.60, 0.71)

−0.19 (−0.28, −0.09)

−0.20 (−0.29, −0.10)

SAT rho (95% CI)

0.006

0.01

0.8

0.095

0.03

0.002

<0.001

<0.001

0.6

<0.001

<0.001

<0.001

p-value

375

375

376

402

403

403

402

373

402

403

402

402

N

0.37 (0.28, 0.46)

−0.06 (−0.16, 0.04)

−0.24 (−0.33, −0.14)

−0.03 (−0.13, 0.07)

−0.09 (−0.18, 0.01)

0.12 (0.02, 0.21)

0.04 (−0.06, 0.14)

0.31 (0.22, 0.40)

−0.10 (−0.19, 0.00)

0.24 (0.15, 0.33)

−0.44 (−0.52, −0.36)

−0.41 (−0.49, −0.33)

Intrahepatic fat rho (95% CI)

Spearman correlation between cardiometabolic risk factors, VAT, SAT, and intrahepatic fat

<0.001

0.2

<0.001

0.5

0.08

0.020

0.4

<0.001

0.05

<0.001

<0.001

<0.001

p-value

Author Manuscript
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372
401
402
402
401
375
374
374

IL1-Beta

IL6

TNFAR1

TNFAR2

HDL cholesterol

LDL cholesterol

Triglycerides

402

Leptin

HOMA IR

401

HMW Adiponectin

401

401

Total Adiponectin

Resistin

N

Factor

0.16 (0.06, 0.26)

−0.00 (−0.10, 0.10)

−0.19 (−0.28, −0.09)

−0.01 (−0.10, 0.09)

−0.01 (−0.11, 0.08)

0.28 (0.19, 0.37)

0.04 (−0.05, 0.14)

0.38 (0.29, 0.46)

0.05 (−0.05, 0.14)

0.60 (0.54, 0.66)

−0.31 (−0.40, −0.22)

−0.31 (−0.40, −0.22)

BMI rho (95% CI)

0.001

0.9

<0.001

0.9

0.8

<0.001

0.4

<0.001

0.4

<0.001

<0.001

<0.001

p-value

339

339

340

362

363

363

362

337

362

363

362

362

N

0.17 (0.06, 0.27)

−0.10 (−0.21, 0.00)

−0.27 (−0.36, −0.16)

−0.03 (−0.13, 0.08)

0.03 (−0.08, 0.13)

0.28 (0.18, 0.37)

0.05 (−0.06, 0.15)

0.38 (0.29, 0.47)

0.02 (−0.09, 0.12)

0.44 (0.35, 0.52)

−0.35 (−0.43, −0.25)

−0.33 (−0.42, −0.23)

Waist Circumference rho (95% CI)

0.002

0.05

<0.001

0.6

0.6

<0.001

0.4

<0.001

0.7

<0.001

<0.001

<0.001

p-value

366

366

366

392

393

393

392

363

392

393

392

392

N

Author Manuscript

Spearman correlation between cardiometabolic risk factors BMI, WC and physical function

−0.01 (−0.11, 0.09)

−0.03 (−0.13, 0.07)

−0.02 (−0.12, 0.08)

0.15 (0.06, 0.25)

0.26 (0.16, 0.35)

0.34 (0.25, 0.43)

−0.01 (−0.11, 0.09)

0.07 (−0.03, 0.17)

0.18 (0.08, 0.27)

0.35 (0.26, 0.44)

0.01 (−0.09, 0.11)

0.05 (−0.05, 0.14)

400m walk time rho (95% CI)

0.8

0.5

0.7

0.002

<0.001

<0.001

0.9

0.2

<0.001

<0.001

0.8

0.4

p-value

Author Manuscript
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Table 3.

Author Manuscript

Multivariable linear regression of adipokines, insulin resistance, inflammatory markers (log-transformed) and
lipid profile with VAT, SAT, intrahepatic fat, and physical function
Outcome

Author Manuscript
Author Manuscript
Author Manuscript

N

Estimate (per 1 SD increase)

StdErr

Probt

Total adiponectin

402

−0.30

0.04

<0.001

HMW adiponectin

402

−0.31

0.04

<0.001

Leptin

403

0.48

0.05

<0.001

Resistin

402

0.05

0.03

0.09

HOMA

373

0.22

0.05

<0.001

IL6

403

0.04

0.05

0.3

TNFAR1

403

−0.00

0.01

0.9

TNFAR2

402

0.01

0.02

0.7

HDL cholesterol

376

−0.07

0.02

<0.001

LDL

375

1.3

2.3

0.5

Triglycerides

375

0.16

0.03

<0.001

Total adiponectin

402

−0.21

0.04

<0.001

HMW adiponectin

402

−0.22

0.04

<0.001

Leptin

403

0.61

0.05

<0.001

Resistin

402

0.03

0.03

0.2

HOMA

373

0.17

0.05

<0.001

IL6

403

0.08

0.04

0.07

TNFAR1

403

0.00

0.01

0.8

TNFAR2

402

−0.00

0.02

0.9

HDL cholesterol

376

−0.05

0.02

0.007

LDL

375

2.7

2.2

0.2

Triglycerides

375

0.07

0.03

0.009

Total adiponectin

402

−0.31

0.04

<0.001

HMW adiponectin

402

−0.36

0.04

<0.001

Leptin

403

0.35

0.05

<0.001

Resistin

402

0.01

0.03

0.8

HOMA

373

0.25

0.04

<0.001

IL6

403

0.11

0.04

0.007

TNFAR1

403

0.01

0.01

0.5

TNFAR2

402

0.02

0.02

0.3

HDL cholesterol

376

−0.08

0.02

<0.001

LDL

375

−2.7

2.2

0.2

Triglycerides

375

0.19

0.02

<0.001

VAT

SAT

Intrahepatic fat
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N

Estimate (per 1 SD increase)

StdErr

Probt

Total adiponectin

392

0.09

0.05

0.05

HMW adiponectin

392

0.05

0.05

0.3

Leptin

393

0.10

0.05

0.04

Resistin

392

0.04

0.03

0.2

HOMA

363

−0.06

0.05

0.2

IL6

393

0.13

0.05

0.006

TNFAR1

393

0.06

0.02

<0.001

TNFAR2

392

0.01

0.02

0.7

HDL cholesterol

366

−0.03

0.02

0.2

LDL

366

−2.4

2.5

0.3

Triglycerides

366

−0.03

0.03

0.4

400 m walk time
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*

Adjusted for age, sex, race, diabetes, hypertension, hypercholesterolemia (except for outcomes HDL, LDL and triglycerides), cardiovascular
disease, PVD, eGFR, proteinuria.
Models with walk total seconds are also adjusted for BMI.
Estimates obtained from 5 datasets with imputed covariate values created with multiple imputation and MI analyze.
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